AI Article Synopsis
- Chronic kidney disease (CKD) is linked to high mortality rates, particularly from cardiovascular issues, and elevated heart rate is identified as a risk factor.
- A study involving 54 non-dialysis stage 5 CKD patients found that serum endocan levels and hypertension history significantly predict night/day heart rate variability.
- The results suggest that higher serum endocan is associated with changes in heart rate patterns, indicating a need for further research into treatments that lower serum endocan levels in these patients.
Article Abstract
Background: Chronic kidney disease (CKD) is very common now and is associated with high overall and cardiovascular mortality. Numerous studies have reported that elevated heart rate (HR) is a risk factor for cardiovascular mortality. We investigated the link between serum endocan and circadian heart rate variability in non-dialysis stage 5 CKD patients.
Methods: In a cross-sectional study, we enrolled 54 prevalent n non-dialysis stage 5 CKD patients (32 males, aged 48.2 ± 14.92 years). HR was measured with an automatic system. Serum endocan level was analyzed by ELISA.
Results: Night/day HR ratio was independently predicted by serum endocan level (P < 0.01) and hypertension history (P < 0.05). Adjusted R of the model was 0.222.
Conclusion: Increased serum endocan is significantly associated with circadian heart rate variability in non-dialysis stage 5 CKD patients. Further investigation is needed to explore the potential benefits of serum endocan lowering therapy in this patient group.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11255-018-1993-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!